| Angiotensin II for the treatment of vasodilatory shock A Khanna, SW English, XS Wang, K Ham, J Tumlin, H Szerlip, LW Busse, ... New England Journal of Medicine 377 (5), 419-430, 2017 | 702 | 2017 |
| Association between mRNA vaccination and COVID-19 hospitalization and disease severity MW Tenforde, WH Self, K Adams, M Gaglani, AA Ginde, T McNeal, ... Jama 326 (20), 2043-2054, 2021 | 579 | 2021 |
| Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study AS Lauring, MW Tenforde, JD Chappell, M Gaglani, AA Ginde, T McNeal, ... bmj 376, 2022 | 512 | 2022 |
| Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising … WH Self MMWR. Morbidity and mortality weekly report 70, 2021 | 457 | 2021 |
| Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults—United States, March–July 2021 MW Tenforde MMWR. Morbidity and mortality weekly report 70, 2021 | 248 | 2021 |
| Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II JA Tumlin, R Murugan, AM Deane, M Ostermann, LW Busse, KR Ham, ... Critical care medicine 46 (6), 949-957, 2018 | 201 | 2018 |
| Effect of vitamin C, thiamine, and hydrocortisone on ventilator-and vasopressor-free days in patients with sepsis: the VICTAS randomized clinical trial JE Sevransky, RE Rothman, DN Hager, GR Bernard, SM Brown, ... Jama 325 (8), 742-750, 2021 | 200 | 2021 |
| Management of refractory vasodilatory shock JC Jentzer, S Vallabhajosyula, AK Khanna, LS Chawla, LW Busse, ... Chest 154 (2), 416-426, 2018 | 199 | 2018 |
| Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study LS Chawla, L Busse, E Brasha-Mitchell, D Davison, J Honiq, Z Alotaibi, ... Critical care 18, 1-9, 2014 | 175 | 2014 |
| Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States MW Tenforde, MM Patel, AA Ginde, DJ Douin, HK Talbot, JD Casey, ... MedRxiv, 2021 | 157 | 2021 |
| Effectiveness of mRNA vaccination in preventing COVID-19–associated invasive mechanical ventilation and death—United States, March 2021–January 2022 MW Tenforde MMWR. Morbidity and mortality weekly report 71, 2022 | 148 | 2022 |
| Vasoplegic syndrome following cardiothoracic surgery—review of pathophysiology and update of treatment options LW Busse, N Barker, C Petersen Critical Care 24, 1-11, 2020 | 116 | 2020 |
| Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial R Bellomo, LG Forni, LW Busse, MT McCurdy, KR Ham, DW Boldt, ... American journal of respiratory and critical care medicine 202 (9), 1253-1261, 2020 | 115 | 2020 |
| COVID-19 and the RAAS—a potential role for angiotensin II? LW Busse, JH Chow, MT McCurdy, AK Khanna Critical Care 24, 1-4, 2020 | 112 | 2020 |
| The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) Protocol: a prospective, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial DN Hager, MH Hooper, GR Bernard, LW Busse, EW Ely, AA Fowler, ... Trials 20, 1-16, 2019 | 94 | 2019 |
| Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults—United States … MW Tenforde MMWR. Morbidity and mortality weekly report 71, 2022 | 89 | 2022 |
| Effectiveness of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccines for preventing coronavirus disease 2019 hospitalizations in the United States MW Tenforde, MM Patel, AA Ginde, DJ Douin, HK Talbot, JD Casey, ... Clinical infectious diseases 74 (9), 1515-1524, 2022 | 82 | 2022 |
| Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock R Bellomo, RG Wunderink, H Szerlip, SW English, LW Busse, AM Deane, ... Critical Care 24, 1-8, 2020 | 79 | 2020 |
| Novel therapies for acute kidney injury H Chen, LW Busse Kidney International Reports 2 (5), 785-799, 2017 | 78 | 2017 |
| Clinical experience with IV angiotensin II administration: a systematic review of safety LW Busse, XS Wang, DM Chalikonda, KW Finkel, AK Khanna, HM Szerlip, ... Critical Care Medicine 45 (8), 1285-1294, 2017 | 65 | 2017 |
